These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38012333)

  • 1. A practice quit model to test early efficacy of medications for alcohol use disorder in a randomized clinical trial.
    Ray LA; Baskerville WA; Nieto SJ; Grodin E; Enders C; Kady A; Meredith L; Gillis A; Leventhal A; Ho D; Miotto K
    Psychopharmacology (Berl); 2024 Mar; 241(3):543-553. PubMed ID: 38012333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterizing reward and relief/habit drinking profiles in a study of naltrexone, varenicline, and placebo.
    Kady A; Grodin EN; Ray LA
    Alcohol Alcohol; 2024 May; 59(4):. PubMed ID: 38953743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel human laboratory model for screening medications for alcohol use disorder.
    Ho D; Towns B; Grodin EN; Ray LA
    Trials; 2020 Nov; 21(1):947. PubMed ID: 33225963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline.
    Miranda R; O'Malley SS; Treloar Padovano H; Wu R; Falk DE; Ryan ML; Fertig JB; Chun TH; Muvvala SB; Litten RZ
    Alcohol Clin Exp Res; 2020 Jul; 44(7):1431-1443. PubMed ID: 32363592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels.
    Nieto SJ; Enders CK; Witkiewitz K; O'Malley SS; Ray LA
    Alcohol Clin Exp Res; 2022 Dec; 46(12):2258-2266. PubMed ID: 36515648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in Drinking was Associated With Improved Clinical Outcomes in Women With HIV Infection and Unhealthy Alcohol Use: Results From a Randomized Clinical Trial of Oral Naltrexone Versus Placebo.
    Cook RL; Zhou Z; Miguez MJ; Quiros C; Espinoza L; Lewis JE; Brumback B; Bryant K
    Alcohol Clin Exp Res; 2019 Aug; 43(8):1790-1800. PubMed ID: 31373701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leveraging meta-regression to test if medication effects on cue-induced craving are associated with clinical efficacy.
    Nieto SJ; Du H; Meredith LR; Donato S; Magill M; Ray LA
    Psychopharmacology (Berl); 2024 Aug; 241(8):1679-1689. PubMed ID: 38613685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline C-reactive protein levels are predictive of treatment response to a neuroimmune modulator in individuals with an alcohol use disorder: a preliminary study.
    Grodin EN; Meredith LR; Burnette EM; Miotto K; Irwin MR; Ray LA
    Am J Drug Alcohol Abuse; 2023 May; 49(3):333-344. PubMed ID: 36282988
    [No Abstract]   [Full Text] [Related]  

  • 9. Adaptive Smoking Cessation Using Precessation Varenicline or Nicotine Patch: A Randomized Clinical Trial.
    Davis JM; Masclans L; Rose JE
    JAMA Netw Open; 2023 Sep; 6(9):e2332214. PubMed ID: 37682573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial.
    O'Malley SS; Zweben A; Fucito LM; Wu R; Piepmeier ME; Ockert DM; Bold KW; Petrakis I; Muvvala S; Jatlow P; Gueorguieva R
    JAMA Psychiatry; 2018 Feb; 75(2):129-138. PubMed ID: 29261824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data.
    Xenakis JG; Kinter ET; Ishak KJ; Ward AJ; Marton JP; Willke RJ; Davies S; Caro JJ
    Pharmacoeconomics; 2011 Jun; 29(6):497-510. PubMed ID: 21452908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibudilast for alcohol use disorder: study protocol for a phase II randomized clinical trial.
    Burnette EM; Baskerville WA; Grodin EN; Ray LA
    Trials; 2020 Sep; 21(1):779. PubMed ID: 32912290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Combination Treatment With Varenicline and Nicotine Patch on Smoking Cessation Among Smokers Who Drink Heavily: A Randomized Clinical Trial.
    King A; Vena A; de Wit H; Grant JE; Cao D
    JAMA Netw Open; 2022 Mar; 5(3):e220951. PubMed ID: 35244704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.
    Falk DE; O'Malley SS; Witkiewitz K; Anton RF; Litten RZ; Slater M; Kranzler HR; Mann KF; Hasin DS; Johnson B; Meulien D; Ryan M; Fertig J;
    JAMA Psychiatry; 2019 Apr; 76(4):374-381. PubMed ID: 30865232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
    Bogenschutz MP; Ross S; Bhatt S; Baron T; Forcehimes AA; Laska E; Mennenga SE; O'Donnell K; Owens LT; Podrebarac S; Rotrosen J; Tonigan JS; Worth L
    JAMA Psychiatry; 2022 Oct; 79(10):953-962. PubMed ID: 36001306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy for anxiety and comorbid alcohol use disorders.
    Ipser JC; Wilson D; Akindipe TO; Sager C; Stein DJ
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD007505. PubMed ID: 25601826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial.
    Hauser P; Fuller B; Ho SB; Thuras P; Kern S; Dieperink E
    Addiction; 2017 Jul; 112(7):1173-1183. PubMed ID: 28192622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Double-Blind Randomized Placebo-Controlled Trial of Oral Naltrexone for Heavy-Drinking Smokers Seeking Smoking Cessation Treatment.
    Kahler CW; Cioe PA; Tzilos GK; Spillane NS; Leggio L; Ramsey SE; Brown RA; O'Malley SS
    Alcohol Clin Exp Res; 2017 Jun; 41(6):1201-1211. PubMed ID: 28401564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.